Business Wire

ANTECH

23.4.2024 08:01:29 CEST | Business Wire | Press release

Share
Antech’s breakthrough cancer screening tool launches in Europe, supporting early canine cancer detection

Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs, Nu.Q® testing also includes prevalent types of canine cancers, enabling veterinarians and pet owners to make informed decisions about cancer care more quickly.

Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, part of Mars Science & Diagnostics said: “It’s exciting to see innovations like Nu.Q® Canine Cancer Test become more widely available to veterinary teams in Europe. With cancer affecting one in four dogs1, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes. This is what our work at Antech is all about.”

Nu.Q® Canine Cancer Test is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers. Nu.Q® testing, run on the Element i+ analyser, is both cost-effective and simple, requiring only 50µL of EDTA plasma from a patient and providing accurate results in 5 to 10 minutes. Studies2 have shown >75% detection rates for common cancers in dogs like lymphoma and hemangiosarcoma when using Nu.Q®. As the only patient-side in-house test that provides rapid and accurate results from EDTA plasma, the Nu.Q® test is an aid to diagnosis that can be run in clinic by veterinary professionals during annual check-ups or regular senior wellness exams.

Dr. Maximiljan W. Krauss, Dipl. ECVS, Tierklink Düsseldorf, used Nu.Q® Canine Cancer Test first-hand during the pilot phase and commented: “At our clinic, we see around 1500 cases of cancer in dogs a year. Lymphoma and hemangiosarcoma are the most common type of cancer we see affecting dogs as young as five years old. Thanks to Nu.Q® Canine Cancer Test and the Element i+ in-house analyzer, we have a fast and accurate means to screen for cancer, which helps us intervene early and choose the best possible care pathway for every patient. At the end of the day, early interventions can make a real difference to a dog’s quality of life and the time they have to spend with their family.”

Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q® Canine Cancer Test is supplied under license by Belgian Volition SRL.

Nu.Q® will be available in the UK as part of the European launch. For orders and more information about the product, please contact Antech UK.

About Mars Science & Diagnostics and Antech

Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Our veterinary diagnostics business, Antech, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; 90+ reference laboratories around the globe; veterinary imaging and technology; education; and board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel™ DNA test products, the world’s most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health.

1 https://www.avma.org/resources/pet-owners/petcare/cancer-pets#:~:text=Approximately%201%20in%204%20dogs,rate%20of%20cancer%20in%20cats.

2 Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422725707/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release

Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and

Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release

Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co

Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release

Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro

SES to Develop European Direct-to-Device Technologies under ESA Partnership Project17.11.2026 15:30:00 CET | Press release

The new SELYCE programme supports transition towards hybrid networks to strengthen Europe’s critical communications infrastructures SES today announced it will lead the industrial activities of SELYCE, a new European initiative focused on developing the technologies needed to enable future Direct-to-Device (D2D) satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117544892/en/ SES to Develop European Direct-to-Device Technologies under ESA Partnership Project Conducted under a Partnership Project with the European Space Agency (ESA) and supported by the Luxembourg Space Agency (LSA), Belgian Science Policy Office (BELSPO) and UK Space Agency (UKSA), SELYCE brings together European industry and research organisations to advance standards-based 5G Non-Terrestrial Network (NTN) capabilities that will allow everyday smartphones and IoT devices to connect seamlessly via satellite beyond the reach of terrestrial

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye